Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 17/20 | 0.69 |
| ▸ | MTNR1B | P49286 | 17/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4540516 | 0.99 | MTNR1A (0.67) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| Hydrochloric Acid SCHEMBL4540512 | 0.99 | MTNR1A (0.67) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL805875 | 0.94 | MTNR1A (0.71) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL1566592 | 0.93 | MTNR1A (0.66) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL12056685 | 0.87 | MTNR1A (0.67) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL23945053 | 0.86 | MTNR1A (0.72) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL13985221 | 0.83 | MTNR1A (0.72) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL1645941 | 0.83 | MTNR1A (0.68) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL1566589 | 0.82 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL803818 | 0.81 | MTNR1A (0.62) | MTNR1AMTNR1BABCB11SIGMAR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| WO-2012063085-A2 | DRUG DERIVATIVES | REDX PHARMA LIMITED (GB) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225594-A1 | DRUG DERIVATIVES | SQOR, NQO1, CYP2D6 | MTNR1A 950/4885MTNR1B 1014/4885ABCB11 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.